NasdaqGS:BVSMedical Equipment
Bioventus (BVS) Profitability Pivot Challenges Skeptics Despite Slower Revenue Growth Forecasts
Bioventus (BVS) has rounded out FY 2025 with Q4 revenue of US$157.9 million and basic EPS of US$0.22, alongside trailing twelve month revenue of US$568.1 million and basic EPS of US$0.34 that mark a turn into profitability over the past year. The company has seen quarterly revenue move from US$123.9 million and basic EPS of a US$0.04 loss in Q1 2025 to US$157.9 million and US$0.22 in Q4. Trailing twelve month EPS shifted from a US$0.52 loss in Q4 2024 to a US$0.34 profit in Q4 2025, pointing...